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Abstract 
Voltage-gated Na+ channels (VGSCs) in nociceptive neurons are the molecular 
targets for local anaesthetics. However, due to the ubiquity of VGSCs in excitable 
tissues, they are prone to inhibition by local anaesthetics, including the cardiac 
NaV1.5 subtype, which is also expressed in metastatic breast and colon cancer 
cells.The expression and function of NaV1.5 facilitate invasion and migration of colon 
cancer cells. Local anaesthetics inhibit metastatic cancer cell invasion in vitro by 
inhibiting NaV1.5 VGSCs, which may contribute to a direct mechanism by which 
regional anaesthesia during tumour resection reduces subsequent cancer 
recurrence. Metastatic colon cancer cells express adult and neonatal NaV1.5 splice 
variants. Lidocaine and levobupivacaine are amide local anaesthetics that are widely 
used in the clinic. They have different physiochemical properties and thus differ in 
their pharmacokinetic and pharmacodynamic profile. We compared the mechanisms 
of action of these two local anaesthetics on adult and neonatal NaV1.5 
channelsrecombinantly expressed inhuman embryonic kidney cells usingwhole cell 
voltage-clamp.Lidocaine and levobupivacaine inhibited adult and neonatal NaV1.5 in 
a state-dependent manner. Both drugs required the inactivated state of the channel 
for inhibition within the concentration range tested. Lidocaine and levobupivacaine 
stabilised the inactivated state, resulting in significant hyperpolarising shifts in the 
V1/2 of inactivation, while neither affected the V1/2 of activation. Levobupivacaine was 
approximately 10-fold more potent than lidocaine. The potency of both local 
anaesthetics was similar on adult and neonatal splice variants. The neonatal NaV1.5 
variant recovered more readily than the adult from lidocaine blockade. On the other 
hand, blockade by levobupivacaine of both splice variants, upon recovery from 
inactivation, was irreversible within the time scale examined. These findings are 
discussed in the context of their implications for cardiac toxicity and putative 
antimetastatic effects of local anaesthetics. 
 
 
 
ii 
 
 
Dedication 
 
To my loving parents, Rasem and Nadia, who have always offered their relentless 
support. 
To my late grandfather, Khalifa and my grandmother, Fatima,who always 
encouraged me to seek knowledge. 
To my sister, Nada, and my brothers Mohammed, Hamza and Omar who always 
stood by my side, even though we are miles apart. 
I express my deepest gratitude to you all and thank you sincerely for all your efforts 
and support and for being the best family one can ever have.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
Acknowledgments 
 
I would like to express the deepest appreciation to my supervisor Professor Tim 
Hales for all his guidance and support throughout my research.  
 
I would also like to thank all the lab members for their help and for creating a lovely 
work atmosphere. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
 
Declaration  
I declare that the content of this project report is my own work and has not previously 
been submitted for any other assessment. The report is written in my own words and 
conforms to the University of Dundee’s Policy on plagiarism and academic 
dishonesty. Unless otherwise indicated, I have consulted all of the references cited in 
this report. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature:    Date:  22.12.2015 
 
 
 
 
 
v 
 
 
Table of contents  
................................................................................................................. Error! Bookmark not defined. 
1. Introduction ............................................................................................................ 1 
1.1 The metastatic cascade .................................................................................... 1 
1.2 The benefit of local anaesthesia in tumour resection ........................................ 2 
1.3 The role of VGSCs in metastasis ...................................................................... 4 
1.3.1 VGSCs: structure and function ................................................................... 4 
1.3.2 Noncanonical roles of VGSCs .................................................................... 8 
1.3.3 VGSCs as key regulators of cancer metastasis.......................................... 9 
1.3.4 Pharmacology of VGSCs.......................................................................... 10 
1.4 Local anaesthetics .......................................................................................... 11 
1.5 VGSCs blockers as anti-metastatic drugs....................................................... 15 
1.6 Project aims ................................................................................................ 17 
2. Materials and methods ......................................................................................... 17 
2.1 Plasmid preparation ........................................................................................ 17 
2.2 Cell culture and transfection............................................................................ 17 
2.3 Electrophysiology............................................................................................ 18 
2.4 Statistics and data analysis............................................................................. 19 
3. Results ................................................................................................................. 21 
3.1 Inhibition of adult and neonatal NaV1.5 by lidocaine and levobupivacaine..... 21 
3.2 The effects of lidocaine and levobupivacaine on the voltage-dependence of 
activation of adult and neonatal NaV1.5 ................................................................ 24 
3.3 The effects of lidocaine and levobupivacaine on the voltage-dependence of 
inactivation of adult and neonatal NaV1.5 ............................................................. 27 
3.4 Resting-state and use-dependent block by lidocaine and levobupivacaine .... 31 
3.5 Recovery from inactivation and block by lidocaine and levobupivacaine ........ 37 
4. Discussion............................................................................................................ 41 
4.1 Summary......................................................................................................... 41 
vi 
 
 
4.2 Technical considerations................................................................................. 41 
4.3 The mode of action of lidocaine and levobupivacaine on adult and neonatal 
NaV1.5................................................................................................................... 42 
4.4 Hydrophobicity and LAs mechanism of action ................................................ 44 
4.5 Scope for selectivity ........................................................................................ 44 
4.6 Clinical implications:........................................................................................ 45 
5.  Future work ......................................................................................................... 47 
5.1 Local anaesthesia in tumour resection............................................................ 47 
5.2 The effects of lidocaine and levobupivacaine on fast and slow inactivation.... 48 
5.3 Time course of recovery from local anaesthetic blockade............................... 48 
5.4 The Invasion machinery of metastatic colon cancer cells ............................... 49 
6. References........................................................................................................... 51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
 
 
List of figures 
 
Figure 1.1 Diagrammatic illustration of the metastatic cascade................................. 2 
Figure 1.2 Summary of the benefits of local anaesthesia in tumour surgery. ............ 4 
Figure 1.3 Structure and gating of voltage-gated sodium channels (VGSCs).. ......... 7 
Figure 1.4 Schematic representation of the NaV1.5 α-subunit highlighting the 
difference in amino acids between the adult and neonatal splice variants. ................ 8 
Figure 1.5 The chemical structure of lidocaine, levobupivacaine and ropivacaine. . 13 
Figure 3.1Concentration-response relationship for lidocaine and levobupivacaine on 
adult and neonatal NaV1.5........................................................................................ 22 
Figure 3.2 The effects of lidocaine and levobupivacaine on the voltage-dependence 
of activation of adult and neonatal NaV1.5................................................................ 26 
Figure 3.3 Lidocaine and levobupivacaine influence the voltage-dependence of 
inactivation of adult and neonatal NaV1.5................................................................. 29 
Figure 3.4 The effects of lidocaine and levobupivacaine on the voltage-dependence 
of inactivation at -120 mV......................................................................................... 30 
Figure 3.5 Lidocaine and levobupivacaine inhibit adult and neonatal NaV1.5 in a 
state-dependent manner. ......................................................................................... 34 
Figure 3.6 Use-dependent block by lidocaine and levobupivacaine of adult and 
neonatal NaV1.5 at -80, -90 and -120 mV................................................................. 36 
Figure 3.7 Recovery from inactivation at -80 mV of adult and neonatal NaV1.5. ..... 38 
Figure 3.8  Recovery from inactivation of adult and neonatal NaV1.5 in the presence 
of lidocaine and levobupivacaine.. ........................................................................... 39 
 
 
 
 
 
 
 
viii 
 
 
List of tables  
Table 1.1 Subtypes of VGSCs found in cancer cells. ................................................ 9 
Table 1.2 Physicoochemical properties of clinically used local anaesthetics ........... 12 
Table 3.1 Summary of IC50 values of lidocaine and levobupivacaine on adult and 
neonatal NaV1.5. ...................................................................................................... 23 
Table 3.2 Summary of electrophysiological parameters of adult and neonatal NaV1.5 
in the absence and presence of lidocaine and levobupivacaine............................... 31 
Table 3.3 Summary of the time constants of recovery from inactivation and block by 
lidocaine and levobupivacaine.. ............................................................................... 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
 
 
List of abbreviations  
 
ATX: anemone toxin 
EGTA: Ethylene glycol tetraacetic acid 
FBS: Foetal bovine serum 
GA: General anaesthetic 
HEK: Human embryonic kidney cells 
HEPES: 4-(2-hydroxyethyl)-peiperazineethanesulfonic acid 
LA: Local anaesthetic 
IC50:The concentration which produces half maximal inhibition   
IV: Intravenous 
NCX: Sodium-calcium exchanger 
NHE: Sodium hydrogen exchanger 
PABA: para-aminobenzoic acid  
TTX: Tetrodotoxin 
VGSC: Voltage-gated sodium ion channel 
V1/2:The voltage at which activation/inactivation is half maximal  
1 
 
 
 
1. Introduction 
 
1.1 The metastatic cascade 
 
Cancer is a collective term for diseases that are characterised by 
uncontrolled cell growth, and the ability of these cells to migrate and invade 
other tissues. The initial defect in cancer is genetic damage to either tumour 
suppressor genes, or cancer promoting (oncogenes), which result in over-
proliferation and primary tumerogenesis1. As the tumours increase in size its 
centre becomes hypoxic, which triggers the expression of angiogenesis 
(blood vessel formation) promoting genes2. The growing tumour is then able 
to receive nutrients and excrete metabolic waste via its own blood supply. 
Further growth favours the accumulation of more genetic changes leading to 
more aggressive behaviours whereby the cancer cells start invading 
surrounding tissues2. Invasion is initiated by detachment from the primary 
tumour, followed by increased motility and digestion of surrounding 
basement membrane through the action of proteolytic enzymes2,3_ENREF_2. 
Once the cells reach the circulation in a process called intravasation, they 
can spread around the body and migrate via the blood or lymph. Migrating 
cells are subject to metabolic and physical stress and most cells undergo 
anoikis, a specific from of apoptosis2. However, surviving cells can lodge into 
distant sites in a process called extravasation, where they either lie dormant 
for years or form secondary tumours immediately. Metastasis is the overall 
process of secondary tumour formation and it is the main cause of death in 
cancer patients.  
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Figure 1.1Diagrammatic illustration of the metastatic cascade highlighting 
the main stages from primary tumorigenesis to formation of secondary 
tumours. 
 
1.2 The benefit of local anaesthesia in tumour resection 
For many cancers, the first-line treatment is surgery. However, surgery can 
liberate metastatic cancer cells into the circulation, a phenomenon termed 
the showering effect4,5_ENREF_4. Those cells can then either re-seed or self-
seed and form secondary tumours5-7, thus increasing the incidence of 
recurrence. According to several retrospective studies, the use of local 
anaesthesia during tumour resection has the benefit of improving surgery 
outcome and lowering the incidence of recurrence8-11. Accordingly, there are 
ongoing clinical trials investigating the effect of local anaesthesia on cancer 
recurrence in operable tumours.To date, there is only one phase 3 
randomised controlled clinical trial to assess the effects of blockade of 
VGSCs by lidocaine in India. The outcomes under investigation are disease 
free interval and long-term survival in operable breast cancer, which will be 
assessed in 2021(ClinicalTrials.gov Identifier: NCT01916317).  It is also 
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noteworthy that a number of retrospective studies to assess anaesthetic 
technique showed no clear correlation between local anaesthesia and cancer 
survival or recurrence12-14_ENREF_12. Such results, however, must be carefully 
interpreted, as other confounding variables were not ruled out and the 
causes of death were not indicated. The benefit of local anaesthesia to 
cancer survival is said to be a result of the following mechanisms.  
Lowering the general anaesthetic and opioid dose: General anaesthetics 
(GAs) have an immunosuppressive effect that results in compromising the 
patient’s cell-mediated immune response and increases the likelihood of 
positive circulating metastatic cells15. Most GAs cause cytotoxicity to natural 
killer cells16. Similarly, opioids, particularly morphine have an inhibitory effect 
on humoral and cellular immune functions in humans15. Considering the 
potential deleterious effects of both GAs and opioids on cancer surgery 
outcome, minimising their required dose might improve outcome and 
recovery. This can be achieved via administration of local anaesthetics.  
Effects on tumour progression: Amide-linked local anaesthetics, such as 
lidocaine and ropivacaine have anti-inflammatory actions via inhibition of c-
src phosphorylation, which is pivotal for signalling the epithelial-
mesenchymal transition17. The latter is necessary for solid tumour 
metastasis.  Inhibition of c-src phosphorylation also inhibits intracellular 
adhesion molecule 1 (ICAM1), which facilitates extravasation18. Persistent 
inflammation is said to exacerbate carcinogenesis and mediates the cellular 
processes that are necessary for the development of the aggressive 
neoplastic phenotype. As such, the anti-inflammatory actions of LAs may 
reduce the risks of cancer surgery. Figure 1.2 provides a summary of the 
mechanisms by which local anaesthesia may affect surgery outcome and 
cancer recurrence.   
Nevertheless, the aforementioned mechanisms are indirect. There is 
mounting evidence to suggest that the benefits of LAs to reduce tumour 
metastasis after surgery is via inhibition of voltage-gated sodium ion 
channels (VGSCs), which are upregulated in many metastatic cancer cells.  
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Figure 1.2Summary of the benefits of local anaesthesia in tumour surgery 
indicating direct and indirect proposed mechanisms. 
 
1.3 The role of VGSCs in metastasis 
 
1.3.1 VGSCs: structure and function 
VGSCs are multimolecularprotein complexes that span the plasma 
membrane. They consist of an obligate pore-forming alpha-subunit that is 
260 KDa and is encoded by 9 different genes (SCN1A-SCN11A), in addition 
to one or two auxiliary beta-subunits of 30-40 KDa that are encoded by the 
genes SCN1B-SCN4B19.  
The alpha subunit comprises four homologous domains (D1-D4), each 
consisting of 6 transmembrane segments (S1-S6). The fourth alpha-helical 
segment (S4) is a voltage-sensor, which contains positively-charged amino 
acid residues, mainly arginines, at every third position20. The S5, S6 and the 
connecting pore-loops link together to from the pore domain. The pore 
domain contains the selectivity filter, consisting of four residues (DEKA)21, 
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which is the narrowest region of the pore that selectively allows the passage 
of hydrated sodium ions. New structural data revealed the existence of 
additional lateral lipid-filled opening, termed, fenestrations, that link the 
membrane to the channel pore. These fenestrations are important access 
pathways for small hydrophobic drug molecules21.     
The inactivation gate consists of the intracellular loop between D3 and 
D422,23_ENREF_19. Three amino acids, namely isoleucine, phenylalanine and 
methionine (IFM) form a key motif for fast inactivation. Channels with 
mutated IFM motifs show slowed inactivation, which can be restored using 
peptides containing this motif. The inactivation gate acts as a hinged lid and 
folds inwards to occlude the pore upon fast inactivation24. The activation gate 
is made up of four residues from each of the intracellular ends of the S6 
segment. This structure provides an intracellular cavity and it is highly 
conserved in VGSCs21. 
VGSCs display voltage-dependent gating. At rest (under hyperpolarised 
potentials), the probability of the channel to exist in an open state is low, and 
thus it predominantly assumes a closed conformation, where sodium ions 
are denied entry. Activation occurs in response to depolarisation, which is 
mediated via the outward movement of the voltage sensor that subsequently 
opens the pore and allows sodium ions into the cytosol25. Within 1-2 ms, the 
channel assumes a non-conducting state and the inactivation gate occludes 
the pore preventing further sodium ions influx. The rate of inactivation varies 
according to the subtype of expressed alpha subunit. It is suggested that fast 
inactivation occurs as a consequence of activation and hence the two 
processes are coupled. There also exists a second inactivated state (slow-
inactivation), which is initiated by prolonged depolarisations26.  There also 
exists a persistent component of the Na+ current (INaP), which unlike the 
transient current, is resistant to inactivation for seconds. The INaPmay result 
from conformational changes to the channel as a result of post-translational 
modification, e.g. phosphorylation. More importantly, it has been shown to be 
upregulated in conditions such as hypoxia, which predominates in cancer 
cells and therefore may contribute to the overall increase of intracellular 
Na+27. 
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In addition to voltage across the membrane, the conformation of VGSCs is 
influenced by the presence of beta-subunits, which modulate gating, post-
translational modifications, such as phosphorylation; and the presence of 
pharmacological agents21. Some VGSCs also display mechanosensitivity, 
which influences their kinetics and voltage-dependence of activation and 
inactivation28. 
The expression of VGSCs is tissue-specific. NaV1.1, NaV1.2 and NaV1.3 are 
mainly expressed in the central nervous system, while NaV1.6 is expressed 
in both, central and peripheral nervous systems21. NaV1.7, NaV1.8 and 
NaV1.9 are primarily restricted to the peripheral nervous system
21. NaV1.4 
and NaV1.5 are expressed in skeletal and cardiac muscles, respectively
21.  
The canonical role of VGSCs is action potential initiation and propagation 
along nerve and muscle fibres, which underlie multiple functions, from 
nociception to muscle contraction.  
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Figure 1.3Structure and gating of voltage-gated sodium channels (VGSCs). 
(A) Topology of the alpha subunit of VGSCs, showing the four domains (I-
IV), with 6 transmembrane segments. The S4 indicated in red is the voltage 
sensor. The pore is made up from segments 5 and 6. (B) Drawing of the 
alpha subunit structure showing the three dimensional arrangement of the 
domains (I-IV) within the lipid bilayer. (C) Gating model of VGSCs illustrating 
the different conformational states. C= closed, O= open, I1= fast inactivation 
and I2= slow inactivation. 
 
The SCN5A encoding the α-subunit of the cardiac VGSC undergoes 
alternative splicing, resulting in isoforms with unique functional properties. In 
metastatic cancer cells, two splice variants are identified, namely adult and 
neonatal29 that differ in exon 6 that correspond to the S3, S3-S4 linker and 
S4 that forms the first voltage sensor, resulting in a substitution of 7 amino 
acids, as illustrated in Figure 1.4. One charge substitution occurs at position 
211, where an aspartate is substituted for a lysine in the neonatal splice 
variant, which was shown to be the main determinant of the functional 
differences between the adult and neonatal splice variant. The neonatal 
NaV1.5 displays slower inactivation and recovery from inactivation kinetics, 
as well as a more depolarised V1/2 of activation, compared to the adult
30. 
Despite the conservation of the LAs binding site, the differences in the 
kinetics may indirectly influence the pharmacology of these splice 
variants,given that LAs are state-dependent blockers.  
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Figure 1.4 Schematic representation of the NaV1.5 α-subunit highlighting the 
difference in amino acids between the adult and neonatal splice variants. 
The top panel illustrates the region in the translated protein that corresponds 
to the site of splicing. The bottom panel shows exon 6, which is affected by 
the splicing. Usage of either exon 6B or exon 6A results in mRNA encoding 
the adult NaV1.5, or the neonatal NaV1.5, respectively. The non-conserved 
amino acids in the neonatal splice variant are highlighted in red.29 
 
1.3.2 Noncanonical roles of VGSCs 
VGSCs are identified in many non-excitable cells where they participate in a 
plethora of cellular processes from proliferation to migration31. Such 
processes are vital for embryogenesis during development, as well as tissue 
repair. Various studies indicate the necessity for VGSCs in heart and brain 
development in mice32-34. In addition, mutations in voltage-gated ion 
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channels are associated with increased risk of craniofacial and limb 
defects35-37. Foetal exposure to VGSCs inhibitors also increases the risk of 
birth abnormalities38-40. The non-excitable roles of VGSCs would explain the 
incentive for their upregulation in cancer cells to acquire a highly invasive 
phenotype.  
 
1.3.3 VGSCs as key regulators of cancer metastasis 
Various subtypes VGSC-α subunit are functionally expressed in several 
cancer cell lines, particularly those that are metastatic (Table 1).  
 
Cancer type VGSC-α subtypes 
Colon Nav1.5 (adult and neonatal)
41 
Breast Nav1.5 (neonatal) and Nav1.7
42,43 
Prostate Nav1.9 and Nav1.7
44,45 
Cervix Nav1.6
46 
Ovary Nav1.5 and Nav1.1
47 
Small-cell and non-small-cell 
lung cancer 
Nav1.7 and Nav1.9
48,49 
Lymphoma Nav1.9
50 
Neuroblastoma Nav1.5
51 
Melanoma NaV1.6
52 
Mesothelioma NaV1.2, NaV1.6 and NaV1.7
53 
 
Table 1.1 Subtypes of VGSCs found in cancer cells. 
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Numerous studies indicate that VGSC function contributes to several 
metastatic cell behaviours. Gene silencing studies showed that 
downregulation of VGSC through small interfering RNAs reduced invasion 
and migration in several cancer cell lines41,43,44,54. Interestingly, gene 
silencing had no effect on cell proliferation in all of these studies. Conversely, 
overexpression of VGSCs favours metastatic cell behaviour by increasing 
invasion. A study was carried out on weakly metastatic prostate cancer cells, 
where the NaV1.4 was overexpressed and it resulted in an increase of 
invasiveness55.  
Pharmacological inhibition of VGSCs produces the same result. The highly 
selective neurotoxin TTX inhibited various metastatic cell behaviours in 
multiple human and rodent cancer cell lines41,42,47,48,55-59. Moreover, local 
anaesthetics, such as lidocaine and ropivacaine have been shown to be 
potent inhibitors of invasion of metastatic colon cancer cells29,41. On the other 
hand, VGSC activators, such as veratridine and anemone toxin (ATX) have 
been shown to enhance invasiveness and motility41,60.  VGSC blockers have 
also been proven effective in inhibiting metastasis in animal models. When 
directly applied to the primary tumour, TTX was shown to significantly reduce 
lung metastasis in the Dunning rat model of prostate cancer61. No effects 
were noticed on cell proliferation and the animals lived significantly longer. 
Additionally, systemic administration of RS10064262, an analogue of 
mexelitine and an inhibitor of TTX-R VGSCs resulted in prolonged survival63. 
Downregulation of NaV1.5 in an orthotopic breast cancer model reduces 
metastasis to liver, lungs and spleen64.   
The notion that VGSC activity is necessary for metastasis is backed up by 
evidence from clinical studies. It was shown that intra-tumour sodium levels 
are elevated in metastatic cells compared to none metastatic ones65-67. 
Furthermore, high levels of expression of Nav mRNA are associated with 
increased risk of metastasis and higher incidence of recurrence42,68. 
1.3.4 Pharmacology of VGSCs 
VGSCs are modulated by a variety of neurotoxins, including the pore blocker 
tetrodotoxin (TTX), saxitoxin, µ-conotoxin, betrachotoxin and peptides 
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derived from scorpion and tarantula venom21. They are classified according 
to their TTX-sensitivity. TTX-sensitive subtypes are blocked by nanomolar 
concentrations of TTX, and these include NaV1.1, NaV1.2, NaV1.3, Nav1.4, 
Nav1.6 and NaV1.7. Whereas, TTX-resistant subtypes are only blocked by 
micromolar concentrations of TTX, including Nav1.5, Nav1.8 and NaV1.9
21. A 
wide range of clinically used drugs also modulate VGSC function to treat 
several pathologies including pain, arrhythmia and epilepsy. Local 
anaesthetics (LAs) are one example; they are used to block nociceptive 
nerve fibres to induce anaesthesia and analgesia. They are also used to 
interfere with cardiac VGSCs to treat arrhythmias.  Most VGSC inhibitors are 
state-dependent blockers, i.e. they display differential affinities for different 
channel conformations69. Such properties enhance their selectivity for 
inactivated channels that are more prevalent in pathological conditions and 
thus minimising their side effects.  
1.4 Local anaesthetics 
LAs are a class of drugs that are widely used in the clinic as analgesics and 
antiarrhythmics. They are broadly classified into ester-linked and amide-
linked LAs according to their chemical structure; and the latter are usually 
preferred, as ester compounds are metabolised to para-aminobenzoic acid 
(PABA), which causes anaphylactic responses in some individuals. Amide 
LAs also have a longer half-life, as they escape metabolism by plasma 
pseudocholinesterases. Lidocaine, levobupivacaine and ropivacaine belong 
to the amide-linked group. These compounds share a chemical structure of a 
phenyl ring, an amide-linkage and a peripheral tertiary amine. The 
pharmacokinetic and pharmacodynamics profile of LAs is largely determined 
by three properties: (1) pKa, (2) hydrophobicity and (3) protein binding. LAs 
are amphipathic, i.e. they exist in neutral and chargedforms and the 
proportion of molecules in the neutral membrane-permeant form at 
physiological pH is dependent on their pKa. This property dictates the rate of 
onset of analgesia and thus LAs with a relatively lower pKa will have a faster 
onset. Hydrophobicity determines lipid partitioning, which dictates potency. 
At the nerve level, this influences the diffusion rate across the myelin sheath 
and is affected by nerve diameter. At the molecular level, however, this 
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property influences the access pathway to the channel and may influence the 
ability of the LA molecule to unbind or remain trapped within hydrophobic 
pockets. Lastly, protein binding dictates the duration of action of LAs, as free 
circulating drug is more slowly made available for metabolism.  These 
properties are crucial when selecting LAs for specific therapeutic purposes, 
as well as rational drug design of LA derivatives. The previously discussed 
properties are summarised in the table below for three of the most widely 
used LAs in the clinic. 
 
 
 
 
Local anaesthetic pKa % Ionised (at 
pH 7.4) 
Partition 
coefficient 
(lipid 
solubility) 
% Protein 
binding 
Lidocaine 7.9 76 366 64 
Ropivacaine 8.1 83 775 94 
Levobupivacaine 8.1 83 3420 97 
 
Table 1.2Physicoochemical properties of clinically used local anaesthetics.70 
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Figure 1.5 The chemical structure of lidocaine, levobupivacaine and 
ropivacaine highlighting the tertiary amine group, which is unique in each of 
the three molecules. 
 
As stated previously, the pharmacological effects of LAs come about through 
state-dependent inhibition of VGSCs71. They alter gating by stabilising the 
inactivated conformation. This mechanism was proposed by Hille in the 
modulated receptor hypothesis, which entails that the LA binding site is 
modulated upon depolarisation; and the open and inactivated conformations 
have higher affinities for LAs than the resting state72. This particular mode of 
action is what makes LAs suitable for inhibiting repetitive neuronal firing in 
pathological conditions. Two aromatic residues (phenylalanine 31 and 
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tyrosine 20) in the middle of the D4-S6 segment were first identified as 
crucial residues for LA binding73. Those studies were carried out on rat brain 
NaV1.2 α-subunit using alanine scanning. Further site mapping studies 
identified other regions on D1, D2 and D3 that influence LA binding74. Amino 
acid residues in those regions are highly conserved in all 9 isoforms of the α-
subunit. LAs can access their binding site either via fenestrations within the 
lipid bilayer, or intracellularly after traversing the lipid bilayer. Interestingly, 
the cardiac VGSCs (NaV1.5) contain a unique threonine residue in the D4-S6 
segment, which provides an additional hydrophilic pathway through the 
external surface. Quaternary lidocaine (QX-314), which is membrane-
impermeant, is able to bind cardiac VGSCs from the either side of the 
membrane, however, it can only bind neuronal and skeletal VGSCs when 
applied from the inside75. This raises possibilities for selectively targeting the 
cardiac VGSCs with QX-314. Lidocaine, ropivacaine and bupivacaine inhibit 
cardiac and neuronal VGSCS in a state- and use-dependent manner73,76-78. 
The physiochemical properties of these drugs influence the concentration-
dependence, use-dependence and recovery from block from VGSCs, 
indicating that modest difference may reflect on their differential interactions 
with neuronal and cardiac VGSCs. Moreover,differential gating of NaV1.5 and 
NaV1.7 determine the mode of action of lidocaine and other antiarrhythmic, 
such as mexiletine78. 
LA toxicity can occur when sufficient amounts are absorbed into the 
circulation and they affect excitable tissues such as the CNS and the heart. It 
has an incidence of 1 in 1000 in peripheral nerve block79. The maximum 
tolerated dose for lidocaine and levobupivacaine are 3 mg/kg and 2.5 mg/kg, 
respectively. To minimise systemic toxicity, LAs are usually co-administered 
with a vasoconstrictor, such as adrenaline. Detailed understanding of the 
mechanism of action of LAs pre-clinically is of paramount importance, in 
order to carefully select candidates that are tailored to ameliorate the post-
operative recurrence of cancer following surgical excision.   
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1.5 VGSCs blockers as anti-metastatic drugs 
The previous evidence inevitably directs our attention to Na+ channel 
blockers as potential metastatic tumour suppressors. Re-purposing of 
VGSCs inhibiting drugs may provide an opportunity to rapidly impact clinical 
practice. Yang et al demonstrated this approach using phenytoin, an anti-
convulsant, to reduce invasion of human breast cancer in an animal model68.  
In order to maximise the therapeutic benefit of re-purposing, drug candidates 
have to be thoroughly selected. Ideal candidates would selectively inhibit 
VGSCs on cancer cells with minimal off-target effects. Given the involvement 
of VGSCs in many channnelopathies, the search for selective ligands is a 
popular area of research, particularly for analgesia and pain management. 
However, drug binding sites on VGSCs are highly conserved21, in addition to 
their ubiquitous expression; and thus selective targeting has proven to be a 
major challenge. Nonetheless, the expression of neonatal isoforms in 
colorectal and breast cancer cells can be exploited to achieve selectivity, 
given that this isoform is absent in cardiac tissue of adults. The neonatal 
NaV1.5 differs from the adult in 7 amino acids in exon 6 as a result of 
alternative splicing29,30. This region corresponds to the voltage-sensor in 
domain I on the translated protein. The neonatal isoform thus differs from the 
adult in the voltage-dependence of activation, as well as the kinetics of 
inactivation. However, no differences in drug binding sites are present. 
Accordingly, LAs such as ropivacaine, which is widely used in the clinic, 
displays no selectivity for either isoform29. Antibody therapy, may offer an 
opportunity to selectively target the neonatal isoform. There has been 
success in producing neonatal-Nav1.5-specific polyclonal antibodies
80.  
Furthermore, state-dependence, an intrinsic property of most clinically used 
VGSC blockers can be exploited to achieve selectivity. As mentioned 
previously, VGSCs blockers, such as LAs have a preference for the 
inactivated state, i.e. they bind with a higher affinity to activated and 
inactivated channels as opposed to resting ones. Under physiological 
conditions, VGSCs cycle through the different states and the inactivated 
state is rarely assumed, i.e. it has a very short lifetime. However, under 
pathological conditions, including pain, arrhythmia and epilepsy, action 
16 
 
 
potential frequency increases and thus inactivation occurs more frequently 
and has a longer lifetime. Consequently, inactivation state-dependent VGSC 
blockers will readily bind to the channel and inhibit its function. In cancer 
cells, the membrane potential is relatively more depolarised. For instance, 
metastatic colorectal cancer cells (SW620) have a membrane potential of -40 
mV29. At such potentials, the majority of the channels are in the inactivated 
state and only a small proportion transition to the activated state according to 
the theoretical window current, which corresponds to the range of potentials 
at which tonic current is present. This is evidenced by the inhibition of 
invasion in vitro and in vivoby TTX, which blocks the pore of the channel and 
denies Na+ influx41,61. In addition, pressure can contribute to the activation of 
the channels as the NaV1.5 are mechanosensitive
28.  Given the large 
proportion of inactivated channels at -40 mV, theywill be more susceptible to 
blockade by drugs, such as LAs. In addition to that, cancer cells are unable 
to fire action potentials and as a result are unable to recover from inactivation 
at rest. Such conditions would favour long-term inhibition by drugs where the 
function of VGSCs can only be reinstated once new channels are inserted 
into the membrane.  
It is known that VGSCs in prostate (Mat-LyLu) cancer cells are auto-
regulated in a positive feedback loop, whereby the activity of the channel 
promotes further Na+ influx and insertion of new channels into the 
membrane58. Therefore, chronic inhibition by local anaesthetics (or other 
VGSC blockers) would serve the benefit of supressing both channel activity 
and expression. This anti-metastatic therapeutic strategy would have a 
twofold advantage.  
Lidocaine, in particular, is a promising candidate, as it can be given 
intravenously either peri-or post operatively. Pre-clinical studies are required 
to determine the safest local anaesthetic with regards to systemic toxicity. 
Low doses of lidocaine are likely to be effective based on 
electrophysiological data showing that cancer cells have a relatively more 
depolarised resting membrane potential, at which most VGSCs will be in the 
inactivated state. Inability to recover from inactivation may render the 
blockade irreversible and thus long-term inhibition is possible with this 
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strategy. Cancer patients would benefit from local anaesthetic derivatives 
that are tailored to target inactivated VGSCs in metastatic tumour cells that 
can be used at low doses to minimise toxicity. Additionally, isoform-selective 
inhibitors would offer novel therapy for metastatic cancer.  
 
1.6 Project aims 
 
This study aims at providing a comparative analysis of the effects of 
lidocaine and levobupivacaine on two splice variants of NaV1.5 found in 
metastatic colon cancer cells, namely adult and neonatal NaV1.5. Human 
embryonic kidney (HEK293) cells are used as heterologous expression 
systems to characterise the effects of lidocaine and levobupivacaine under 
whole-cell voltage clamp. The preclinical investigation will highlight key 
pharmacodynamic aspects of lidocaine and levobupivacaine that can be 
translated for optimal selection of local anaesthetics as anti-metastatic drugs.    
 
2. Materials and methods 
 
2.1 Plasmid preparation 
 
Adult and neonatal NaV1.5 were subcloned into pcDNA3.1 vector 
(Invitrogen). The SCN5A, originally known as human heart 1 (HH1) cDNA 
was a gift from Alfred George. To create the neonatal NaV1.5 pcDNA3.1 
vector, mRNAfragments containing exon 6A from SW620 cells were replaced 
into the same region of the pcDNA3.1-NaV1.5
29. 
2.2Cell culture and transfection 
Human embryonic kidney (HEK293) cells were grown and maintained in 
Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% foetal 
bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen, Paisley, UK). 
Confluent cells were sub-cultured every 3-4 days and plated onto 35 mm 
dishes at low density for electrophysiological experiments. All cells were 
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maintained in an incubator at 37oC and 5 % CO2, except those to be 
transfected using the calcium phosphate precipitation method, which were 
kept at 3.5% CO2. 
HEK293 cells were transiently transfected using the calcium phosphate 
precipitation method with human SCN5A (adult or neonatal) in pcDNA3.1 
vector at 1 µg/dish, along with cDNA for green fluorescent protein at 0.1 
µg/dish29. GFP was used to identify transfected cells.The proportion of 
transfected cells was approximately 60% per dish, 90 % of which on average 
had voltage-activated Na+ currents. Cells were washed from the transfection 
media on day 1 post-transfection and were recorded from on days 2 and 3. A 
minimum of 3 transfected dishes contribute to n numbers, which correspond 
to the number of cells from which data was obtained. 
 
2.3Electrophysiology 
 
Voltage-activated Na+ currents were recorded from HEK-293 cells transiently 
expressing adult or neonatal Nav1.5 using the whole-cell voltage-clamp 
technique. Currents were recorded using an Axopatch 200B patch-clamp 
amplifier, low-pass filtered at 2 KHz, digitised by Digidata 1320A interface, 
sampled at 4 KHz and acquired using pClamp8 software (Molecular Devices, 
CA, USA). Pipettes were formed from borosilicate glass capillaries and had 
resistances between 1.5 and 3 MΩ when filled with intracellular solution, 
containing (in mM) the following: 130 CsCl, 15 NaCl, 2 MgCl2, 10 EGTA and 
10 HEPES. CsCl was used to block K+ currents. The extracellular solution 
contained (in mM) the following: 140 NaCl, 4.7 KCl, 1.2 MgCl2, 2.5 CaCl2, 10 
glucose and 10 HEPES). Recordings were only accepted from cells with the 
following parameters: peak current amplitudes < 5 nA,series resistance < 5 
mΩ and compensatedby ≥ 85 %, and capacitive artefacts with amplitudes < 
30% of the peak current. This selection criteria ensures that voltage errors 
are less than 4 mV. All solutions were bath applied and recordings were 
taken under continuous perfusion of bath solutions at room temperature. No 
corrections were made for the junction potential.  
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A holding potential of –80 mV was used in all protocols unless stated 
otherwise. 
To examine the voltage-dependence of activation, a series of 25-ms voltage 
steps were applied between voltages of -80 mV to +70 mV, in 10 mV 
increments, with an interpulse duration of 5 seconds. The voltage-
dependence of steady-state inactivation was examined using 100 ms 
prepulses to voltages ranging from -140 mV to -10 mV, in 10 mV increments, 
followed by an activation test-pulse to 0 mV. In order to examine use-
independent (resting state) and use-dependent block by local anaesthetics, 
the following protocol was used. Pulses to 0 mV at a frequency of 1 Hz were 
applied under three different holding potentials (-80, -90 and -120 mV). 
Currents were recorded initially under control conditions. The local 
anaesthetics were then applied for 2 minutes to reach steady-state block, 
after which another set of recordings were taken. To examine recovery from 
inactivation and block by local anaesthetics, a step to -120 mV was applied 
at time intervals between 10 to 300 ms,in 10 ms increments. This step was 
used to remove inactivation and hence cause drug unbinding. Currents were 
then activated by a pulse to 0 mV before returning to the holding potential.  
 
2.4Statistics and data analysis 
 
Current amplitudes were measured using pClamp8 (Molecular devices, CA, 
USA). Plots of the voltage-dependence of activation were derived from 
current-voltage relationships. The driving force at each holding potential (up 
to +20 mV) was determined from the theoretical Na+ equilibrium potential, in 
order to calculate Na+ conductance. Conductances were normalised to the 
respective peak values in each cell. Similarly, for the voltage-dependence of 
inactivation currents were normalised to peak amplitude values for each cell. 
Activation and inactivation data were fitted with Boltzmann functions. 
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Where Y is conductance for voltage-dependence of activation, or current for 
voltage-dependence of inactivation , X is voltage, minimum is a constant 
made equal to zero, maximum is a constant made equal to 1, V50is the 
voltage at which activation is half maximal and slope is the steepness of the 
curve.  
Concentration-response data were fitted with a logistic function. Average 
parameters were determined from fits to data acquired from individual cells. 
For recovery from inactivation and block by local anaesthetics, currents were 
normalised to peak values and fitted against the recovery time by single or 
double decay functions. Time constants were determined from data obtained 
from individual cells. 
 Weighted time constants were calculated as follows: 
τw= (τf x Ampf) +(τs x Amps) 
 Where τw is the weighted tau, τs and τs are the fast and slow time constants, 
respectively; and Ampf and Amps are the amplitudes of the fast and slow 
components, respectively. All data are presented as mean ± SEM.  Statistical 
comparisons were performed using the paired or unpaired t-test, or a one-
way ANOVA, as appropriate. Differences were considered significant at p ≤ 
0.05. Fitting and statistical analyses were performed using GraphPad Prism 
software (La Jolla, CA, USA).  
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3.Results 
 
3.1 Inhibition of adult and neonatal NaV1.5 by lidocaine and 
levobupivacaine 
We compared the effects of lidocaine and levobupivacaine (0.3 -30 µM) on 
currents mediated by recombinant adult and neonatal Nav1.5 expressed in 
HEK293 cells. Currents were elicited by a 0 mV step from a holding potential 
of -80 mV before and after drug application to the recording chamber. The 
resulting cumulative concentration-response relationships are shown in 
Figure 3.1. Both lidocaine and levobupivacaine caused potent inhibition of 
NaV1.5-mediated currents. However, there were no differences between 
splice variants with respect to the concentration dependence of inhibition by 
either local anaesthetic (Table 3). Levobupivacaine was approximately 10-
fold more potent than lidocaine, with IC50 values of 1.0 ± 0.2 (n=4) and 3.0 ± 
0.6 µM (n=3) and 20 ± 9.0 and 17 ± 5.0 µM, for levobupivacaine and 
lidocaine on adult and neonatal NaV1.5, respectively.   
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Figure 3.1Concentration-response relationship for lidocaine (A) and 
levobupivacaine (B) on adult and neonatal NaV1.5. Recordings were made 
from HEK293 recombinantly expressing adult or neonatal Nav1.5. Currents 
were elicited by an activating step to 0 mV for 25 ms at 1 Hz, from a holding 
potential of -80 mV. The concentration response relationships were fitted 
using a logistic function. Average parameters were obtained from data 
recorded from individual cells (Table 3.1).  Insets represent exemplary 
currents mediated by adult NaV1.5 in the presence of lidocaine or 
levobupivacaine (0.3-30 µM).  
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IC
50
 (µM) Na
V
 Isoform 
Lidocaine Levobupivacaine 
 
n 
Adult 
20 ± 9.0 1 ± 0.2 4 
Neonatal 
17 ± 5.0 3 ± 0.6 4 
 
Table 3.1 Summary of IC50 values of lidocaine and levobupivacaine on adult 
and neonatal NaV1.5. IC50 values were taken from logistic fits to data from 
individual cells. Statistical analyses were performed using an unpaired t-test. 
No significant differences were observed between the potencies of both LAs 
on either splice variant. 
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3.2 The effects of lidocaine and levobupivacaine on the voltage-
dependence of activation of adult and neonatal NaV1.5 
 
We tested the effects of lidocaine and levobupivacaine on both splice 
variants to determine whether they differentially influence the voltage-
dependence of activation. Paired recordings were taken before and after 
drug application. We used a series of voltage steps from -80 mV to +70 mV 
and recorded the corresponding currents to determine the current-voltage 
relationship. In agreement with previous reports29,30, the neonatal splice 
variant of NaV1.5 had a more depolarised voltage-dependence of activation 
(-26 ± 1 mV, n=11), compared to the adult variant (-33 ± 2 mV, n=14). The 
derived activation curves are shown in Figure 3.2.B and a summary of the 
electrophysiological parameters is provided in table 3.2. Both lidocaine and 
levobupivacaine suppressed currents mediated by adult and neonatal NaV1.5 
over a range of potentials from -80 mV to +20 mV. However, neither drug 
affected the V1/2 of activation (Table 3.2). 
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Figure 3.2The effects of lidocaine and levobupivacaine on the voltage-
dependence of activation of adult and neonatal NaV1.5. Conductances 
obtained from the current-voltage protocol were normalised to their 
respective peak values, and plotted against voltage to establish the 
activation curve. Data points were normalised to peak amplitudes under 
control conditions.  (A) The voltage-protocol with representative currents 
recorded from HEK293 expressing adult NaV1.5 channels, from which the 
voltage-dependence of activation was established. Curves were fitted with 
Boltzmann functions and average parameters are summarised in Table 4 (B) 
The voltage-dependence of activation of currents mediated by adult (solid 
line) and neonatal (dotted line) NaV1.5 channels recorded at -80 mV. (C) and 
(D) represent the voltage-dependence of activation in the absence and 
presence of lidocaine (10 µM), of adult and neonatal NaV1.5, respectively. 
(E) and (F) represent the voltage-dependence of activation in the absence 
and presence of levobupivacaine (1 µM), of adult and neonatal NaV1.5, 
respectively. Both lidocaine and levobupivacaine suppress the conduction of 
both splice variants over potentials between -80 mV and +20 mV, but cause 
no changes to the voltage-dependence of activation. 
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3.3 The effects of lidocaine and levobupivacaine on the voltage-
dependence of inactivation of adult and neonatal NaV1.5 
 
Iexamined the influence of lidocaine and levobupivacaine on the voltage-
dependence of inactivation of currents mediated by NaV1.5. We applied 100 
ms prepulses from -140 mV to -10 mV, followed by an activating step to 0 
mV and examined the proportion of channels that are available for activation. 
The derived inactivation curves are shown in figure 3.3.B. As previously 
reported, there were no significant differences in the voltage-dependence of 
inactivation between the adult and the neonatal splice variants (Table 3.2). 
Both local anaesthetics caused a significant shift in the V1/2 of inactivation of 
currents mediated by both adult and neonatal NaV1.5 VGSCs to more 
hyperpolarised potentials. No differences were observed between splice 
variants with respect to the shift in the V1/2 of inactivation. Interestingly, 
compared to levobupivacaine, lidocaine caused less inhibition at the more 
hyperpolarised potentials from -140 mV to -100 mV (Figure 3.3.C,E). I also 
examined the influence of lidocaine and levobupivacaine on the voltage-
dependence of inactivation at a holding potential of -120 mV, where 
inactivation is absent. No inhibition or shift in the V1/2 of inactivation were 
observed in the presence of either LA (Figure 3.4).   
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Figure 3.3Lidocaine and levobupivacaine influence the voltage-dependence 
of inactivation of adult and neonatal NaV1.5. Current amplitudes recorded 
from the steady-state inactivation protocol were normalised to their 
respective peak amplitudes and plotted against voltage to establish the 
inactivation curve. Curves were fitted with Boltzmann functions and average 
parameters are summarised in Table 4 (A) The steady-state inactivation 
protocol with representative currents mediated by adult NaV1.5 channels, 
from which the voltage-dependence of inactivation was established (B) The 
voltage-dependence of inactivation of currents mediated by the adult (solid 
line) and neonatal (dotted line) NaV1.5 channels. (C) and (D) represent the 
voltage-dependence of inactivation in the presence and absence of lidocaine 
(10 µM), of adult and neonatal NaV1.5, respectively. (E) and (F) represent the 
voltage-dependence of inactivation in the presence and absence of 
levobupivacaine (1 µM), of adult and neonatal NaV1.5, respectively. 
Lidocaine and levobupivacaine significantly caused a hyperpolarising shift to 
the voltage-dependence of inactivation of adult and neonatal NaV1.5 (p < 
0.05, paired t-test). 
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Figure 3.4The effects of lidocaine and levobupivacaine on the voltage-
dependence of inactivation at -120 mV. Voltage-dependence of inactivation 
and Boltzmann fits were performed as previously described in Figure 3.2. 
Lidocaine and levobupivacaine showed no inhibition at -120 mV and had no 
effect on the voltage-dependence of inactivation of currents mediated by the 
adult NaV1.5. 
 
 
Parameter Activation V
1/2
 Activation 
slope 
Inactivation 
V
1/2
 
Inactivation 
slope 
n 
Control  -33 ± 2.0 8.0 ± 0.3 -74 ± 2.0 8.0 ± 0.4 14 
Lidocaine -32 ± 8.0 11.1 ± 0.9* -87 ± 3.0* 12.0 ± 0.7* 14 
Adult 
Na
V
1.5 
Levobupivacaine -30 ± 0.9 11.0 ± 0.4*
 
-85 ± 1.3* 11.0 ± 0.4
 
3 
Control -26 ± 1.0 8.0 ± 0.2 -69 ± 2.0 8.0 ± 0.3 11 
Lidocaine -29  ± 0.9 8.0 ± 0.5 -78 ± 2.0* 11.0 ± 0.5*
 
11 
Neonatal 
Na
V
1.5 
Levobupivacaine -37 ± 3.8 7.0 ± 0.8 -78 ± 1.0* 10.0 ± 0.7*
 
3 
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Table 3.2 Summary of electrophysiological parameters of adult and neonatal 
NaV1.5 in the absence and presence of lidocaine and levobupivacaine. V1/2 
and slope values were taken from the Boltzmann fits to data from individual 
cells. Statistical analyses were performed using a paired t-test. Asterisks 
represent statistically significant differences, ≤ p 0.05. 
 
 
3.4 Resting-state and use-dependent block by lidocaine and 
levobupivacaine 
Local anaesthetics are sensitive to the conformational state of VGSCs. Their 
blockade of VGSCs in nociceptive neurons is use-dependent. We 
investigated state-dependence for lidocaine and levobupivacaine at three 
holding potentials: -80 mV, at which a large proportion (approximately 40 %) 
of the channels are in the inactivated state (Figure 3.3.B ), -90 mV, which is 
the approximate cardiac resting membrane potential; and -120 mV, where 
inactivation is absent. Initially, I determined the time period for lidocaine and 
levobupivacaine to reach steady-state inhibition using a single sweep 
protocol where LAs were applied during stimulation. For both LAs, a 2-
minute incubation was sufficient to reach steady-state inhibition.   In order to 
examine resting-state block currents were elicited by an activating pulse to 0 
mV at 1 Hz before and after a 2-minute drug perfusion under no stimulation. 
The extent of inhibition on the first sweep after steady-state revealed that 
resting-state inhibition was influenced by the holding potential. Both lidocaine 
and levobupivacaine caused the largest inhibition at -80 mV, where 
inactivation is approximately half-maximal. Inhibition at -90 mV, where a 
small proportion of channels are inactivated, was minimal. By contrast, no 
inhibition occurred in the absence of inactivation at -120 mV. Furthermore, 
no differences were observed between the two splice variants with respect to 
resting-state inhibition (Figure 3.5.B,C).  
Use-dependent inhibition was determined by examining the accumulation of 
block in the subsequent sweeps after stimulation was resumed (at 1 Hz). 
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Lidocaine showed no use-dependence at -80 mV, presumably because 
steady-state inhibition had already reached equilibrium in the absence of 
stimulation. Likewise, no systematic use-dependence was observed at -120 
mV where inhibition was negligible, perhaps due to no accumulation of 
inactivation at 1 Hz. By contrast, lidocaine showed inhibition in a use-
dependent manner at -90 mV, only on the adult splice variant (Figure 3.6.A). 
In comparison, levobupivacaine inhibited both splice variants at -80 mV and -
90 mV in a use-dependent manner (Figure 3.6.C, D) No systematic use-
dependence was observed for levobupivacaine at -120 mV.  
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Figure 3.5Lidocaine and levobupivacaine inhibit adult and neonatal NaV1.5 
in a state-dependent manner. (A) Graphical illustration of the protocol used 
to examine resting-state and use-dependent inhibition with exemplary 
currents mediated by adult NaV1.5 channels at -90 mV. Inhibition by 
lidocaine (B) and levobupivacaine (C) was determined at three different 
holding potentials: -80, -90 and -120 mV. Inhibition was determined at rest, 
i.e. in the absence of stimulation by applying the drugs for 2 minutes to reach 
steady-state inhibition, then activating the channels to 0 mV.  Current 
amplitudes were then expressed as a percentage of the average of 5 sweeps 
recorded prior to drug application. For both drugs, the largest inhibition was 
observed at -80 mV, for which potential there is significant inactivation. By 
contrast to -80 mV, inhibition -90 mV was minimal. There was no inhibition at 
-120 mV, a potential at which there is no inactivation. No significant 
differences were observed between the splice variants with respect to 
resting-state inhibition at any of the potentials examined. Inset represents 
exemplary currents mediated by adult Nav1.5 at the tested holding potentials. 
Red and blue traces were recorded in the presence of lidocaine and 
levobupivacaine, respectively. 
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Figure 3.6Use-dependent block by lidocaine and levobupivacaine of adult 
and neonatal NaV1.5 at -80, -90 and -120 mV.Control currents were recorded 
prior to a 2 minute perfusion with local anaesthetics in the absence of 
stimulation. Stimulation was then resumed at 1 Hz for 10 seconds. The 
graphs represent mean current amplitudes recorded for 5 seconds after 
stimulation was resumed, normalised to their respective control values, to 
take systematic run down into consideration. (A) and (B) Use-dependent 
inhibition by lidocaine of currents mediated by adult and neonatal NaV1.5, 
respectively. (C) and (D) Use-dependent inhibition by levobupivacaine of 
currents mediated by adult and neonatal NaV1.5, respectively. Lidocaine 
displayed use-dependent blockade of adult Nav1.5 at a holding potential of -
90 mV. Levobupivacaine displayed use-dependent inhibition of both adult 
and neonatal NaV1.5 at holding potentials of -80 and -90 mV. Mean % control 
values were compared to the first data point after drug perfusion using a 
repeated measures ANOVA, followed by a Dunnett’s multiple comparisons 
test. Asterisks represent statistically significant differences, ≤ p 0.05. 
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3.5Recovery from inactivation and block by lidocaine and 
levobupivacaine 
The differential effects of lidocaine and levobupivacaine on adult and 
neonatal NaV1.5 may arise from their different unbinding kinetics. Therefore, 
we used a protocol designed to examine the rate of recovery from 
inactivation of the two splice variants, in the presence and absence of 
lidocaine and levobupivacaine. We used a holding potential of -80 mV to 
induce inactivation and hence enable inhibition. After that a step to -120 mV 
was applied for durations between 10 to 300 ms to relieve inactivation and 
allow recovery from inactivation. In the absence of LAs, the rate of recovery 
from inactivation at -80 mV appeared slower for the neonatal splice variant 
compared to the adult (Figure 3.7.B), although no significant differences 
were observed between the time constants (Table 3.3).  
The extent of recovery from inactivation in the presence of lidocaine 
compared to levobupivacaine was markedly different (Figure 3.8). Currents 
mediated by the adult splice variant treated with lidocaine recovered by 82 ± 
4 % (n=6), whereas those treated with levobupivacaine recovered by 61 ± 2 
% (n=6) (Figure 3.8.A, B). Lidocaine influenced the recovery rate of the adult 
splice variant, which revealed a fast component that was slowed by 
lidocaine, and a slow one that was not affected. The time constants of 
recovery were 4.0 ± 0.9 ms (n=3) and 6.0 ± 0.7 ms (n=6), in the absence and 
presence of lidocaine, respectively.  Conversely, lidocaine did not affect the 
rate of recovery from block of the neonatal splice variant, which only 
revealed a single fast component of 4 ± 0.6 ms (n=4) and 5 ± 0.6 ms (n=6) in 
the presence and absence of lidocaine, respectively. Recovery from block by 
levobupivacaine was similar for both splice variants with weighted time 
constants of 17 ± 8 ms (n=3) and 13 ± 4 ms (n=3), for adult and neonatal, 
respectively. The time constants of recovery are summarised in Table 5.  
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Figure 3.7Recovery from inactivation at -80 mV of adult and neonatal 
NaV1.5. (A) The rate of recovery from inactivation at -80 mV of adult and 
neonatal NaV1.5 induced by a hyperpolarising step to -120 mV for durations 
between 10 and 300 ms. Currents were normalised to peak values from 
individual cells. Data points were fitted with a double exponential decay 
function. Average parameters obtained from data points taken from individual 
cells are summarised in Table 3.  Inset represents exemplary currents 
mediated by adult NaV1.5 in HEK293 cells. 
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Figure 3.8Recovery from inactivation of adult and neonatal NaV1.5 in the 
presence of lidocaine and levobupivacaine. (A) and (B) represent the rate of 
reversal of lidocaine block of adult and neonatal NaV1.5, respectively. (B) 
and (C) represent the rate of recovery from levobupivacaine block of adult 
and neonatal NaV1.5, respectively. Paired recordings were made before and 
during steady-state inhibition. Reversal of inhibition was induced by a 
hyperpolarising step to -120 mV for durations between 10 and 300 ms. 
Currents were normalised to peak values under control conditions. 
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Parameter Slow time 
constant 
(ms) 
Fast time 
constant 
(ms) 
Fast 
component 
amplitude (%) 
Weighted time 
constant (ms) 
n 
Control 159 ± 28 4 ± 0.9 81 ± 5 30 ± 8 6 
Lidocaine 152 ± 54 6 ± 0.7* 81 ± 3 39 ± 15 3 
Adult 
Na
V
1.5 
Levobupivacaine 99 ± 37 5 ± 0.9 88 ± 3 17 ± 8 3 
Control 168 ± 19 4 ± 0.6 77 ± 8 41 ± 12 6 
Lidocaine N/A 5 ± 0.6 100 4 ± 0.5* 4 
Neonatal 
Na
V
1.5 
Levobupivacaine 87 ± 11 4 ± 0.2 88 ± 5 13 ± 4 3 
 
Table 3.3. Summary of the time constants of recovery from inactivation and 
block by lidocaine and levobupivacaine. Time constants were taken from 
either single or double exponential fits to data from individual cells. Statistical 
analyses were performed using an unpaired t-test. Asterisks represent 
statistically significant differences, ≤ p 0.05. Comparisons were made 
between the time constants in the presence of LAs and the controls. 
 
 
 
 
 
 
41 
 
 
 
 
 
 
4. Discussion 
 
4.1 Summary 
 
Lidocaine and levobupivacaine both potently inhibit currents mediated by 
adult and neonatal NaV1.5, with levobupivacaine being approximately 10-fold 
more potent than lidocaine (Table 3). Neither LA showed selective inhibition 
for either splice variant, or differences with respect to the concentration-
dependence of inhibition. They differ in their mode of action on adult and 
neonatal NaV1.5 as follows. Levobupivacaine is more potent than lidocaine 
and it inhibits both splice variants in a use-dependent manner at a stimulus 
frequency of 1 Hz, unlike lidocaine, which only exhibits use-dependent 
inhibition on the adult splice variant at -90 mV. Moreover, inhibition by 
levobupivacaine is irreversible by hyperpolarisation. Conversely, inhibition by 
lidocaine is readily reversible and splice variant dependent, whereby the rate 
of recovery of the neonatal splice variant is faster than that of the adult. 
These preclinical findings provide useful information for designing a suitable 
regimen for using LAs as anti-metastatic drugs.  In addition, understanding 
the mechanism of action of LAs on the neonatal splice variant has important 
applications in the practice of anaesthesia for neonates.  
 
4.2 Technical considerations 
 
In this study, the mechanism of action of lidocaine and levobupivacaine was 
investigated on adult and neonatal NaV1.5, which are both expressed in 
metastatic colon cancer cells. Although whole-cell recordings can be made 
from the model metastatic cancer cells (SW620), the recombinant system 
was chosen for this study as a means to distinguish between the two splice 
variants, since no selective antagonists are available for either splice variant. 
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However, the recombinant NaV1.5 may not reflect the full electrophysiological 
properties of those in the cancer cells, due to the absence of modulatory 
subunits, such as beta- subunits and other accessory proteins that may 
influence the biophysical properties, as well as the pharmacology of these 
channels. In addition, HEK293 cells express endogenous NaV channels 
when passaged multiple times in culture. Therefore, it is vital not to get 
contamination from these channels and therefore, HEK293 cells were only 
recorded from up to a passage number of 40.  
 
The LAs used in this study are state-dependent blockers that require 
inactivation of the channels in order to cause their inhibitory effects. Since 
inactivation is determined by the voltage, I ensured that the p/6 routine used 
for leak subtraction was carried out after each sweep, to ensure that the 
drugs do not unbind as a result of hyperpolarisation and the subsequent 
removal of inactivation.  
The concentration used in this study, lidocaine (10 µM) and levobupivacaine 
(1 µM) correspond to those achieved systemically during regional 
anaesthesia. Lidocaine has been shown to inhibit invasion in vitro. However, 
to date there is no evidence the inhibition of invasion by levobupivacaine, 
which has proven problematic when used in the matrigel invasion assay 
(unpublished data). This study would be strengthened by including data from 
the matrigel invasion assay with levobupivacaine. 
 
 
4.3The mode of action of lidocaine and levobupivacaine on adult and 
neonatal NaV1.5 
Consistent with previous findings, both LAs exhibited state-dependent 
inhibition73,81. This is evident from the relationship between the holding 
potential, which dictates channel conformation, and the amount of inhibition 
(Figure 3.5.B,C). The extent of inhibition is correlated with the proportion of 
channels in the inactivated state. At -80 mV, where approximately 40% of 
channels are inactivated, the inhibition is larger than that at -90, where only 
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20% of the channels are inactivated (Figure3.3.B). Further to that, both LAs 
caused a significant shift in the voltage-dependence of inactivation, whereas 
neither LA had an effect on the voltage-dependence of activation (Table 4). 
This suggests that the inactivated state is required for LA action, and is 
stabilised in the presence of lidocaine and levobupivacaine.  
In the absence of inactivation (-120 mV), lidocaine (10 µM) and 
levobupivacaine (1µM) both failed to inhibit currents mediated by adult and 
neonatal NaV1.5. Thus, it follows that removal of inactivation should relieve 
the inhibition caused by LAs. I examined the recovery from blockade by LAs 
by using a hyperpolarising step to -120 mV to remove inactivation. The 
results from these experiments revealed differential modes of recovery from 
inhibition by lidocaine and levobupivacaine. Within 300 ms the extent of 
recovery from inhibition by lidocaine is larger than that of levobupivcaine 
(Figure3.8). This suggests that lidocaine unbinds as the channels recover 
from inactivation, while levobupivacaine remains bound despite recovery 
from inactivation within the time scale tested. Interestingly, the unbinding 
mode of lidocaine appears to differ between the two splice variants. The 
extent of recovery of the neonatal splice variant from lidocaine blockade is 
greater than that of the adult splice variant. A striking observation was that 
the time constant of recovery from inactivation of the neonatal splice variant 
only revealed a single component. This may suggest that lidocaine does not 
affect slow inactivation of the neonatal splice variant. By contrast, 
levobupivacaine displays a uniform mode of unbinding from both splice 
variants. Levobupivacaine’s inability to unbind may be due to the different 
route by which it gains access to its binding site, resulting in trapping and 
failure to unbind upon recovery from inactivation. This observation is also 
reflected in the steady-state inactivation data. At hyperpolarised potentials, 
where inactivation is absent, lidocaine seems to cause less inhibition 
compared to levobupivacaine. This is due to unbinding of lidocaine within the 
100 ms pre-pulse and failure of levoubuipvacaine to unbind within the same 
duration.  
Lidocaine and levobupivacaine differ also in their use-dependent inhibition. 
While lidocaine only showed use-dependent inhibition at a holding potential 
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of -90 mV on the adult splice variant, levobupivacaine inhibited both splice 
variants in a use-dependent manner at holding potentials of -80 and -90 mV. 
This is perhaps also a consequence of failure to unbind, which leads to 
accumulation of levobupivacaine upon depolarisation leading to increased 
inhibition. However, in the case of lidocaine, no clear explanation can be 
offered thus far, as the unbinding kinetics at -90 mV may differ between the 
two splice variants, which may underlie the differential use-dependence. At -
80 mV, inhibition seems to have reached steady-state during the 2 minute 
perfusion period and thus no further inhibition occurs upon depolarisation.  
 
 
4.4Hydrophobicity and LAs mechanism of action 
Amide-linked LAs share a common structure of an aromatic ring, a tertiary 
amine group and an intermediate amide linkage. Lidocaine differs from 
levobupivacaine in the tertiary amine group, where it is part of diethyleamine 
in the former and a butylpiperidinein the latter82. Such chemical differences 
reflect on the pharmacokinetic and pharmacodynamics profile of LAs. This 
study suggests that lidocaine unbinds more readily from inactivated NaV1.5 
channels compared to its counterpart, levobupivacaine. The large 
butylpiperidinegroup renders levoubupivacaine more hydrophobic than 
lidocaine.  Hydrophobicity largely influences the potency of LAs at the tissue 
and the molecular level.  The following postulations may explain the 
differential unbinding profile of lidocaine and levobupivacaine. Firstly, it is 
known that hydrophobic LAs can readily gain access into the binding site via 
the fenestrations within the lipid bilayer69. Secondly, hydrophobic molecules 
tend to get trapped within hydrophobic pockets83. Such properties of LAs are 
vital to take into consideration in rational drug design. 
 
4.5Scope for selectivity 
Although VGSCs are ubiquitously expressed in excitable tissues, they exist 
as distinct populations of channels with unique sensitivities to LAs. 
Inactivated VGSCs, which are highly sensitive to LAs have a short half-life 
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under physiological conditions, as the channels transition between closed, 
open and inactivated conformations. However, under pathological conditions, 
e.g. pain and in the case of metastatic colon cancer cells, which have a 
relatively more depolarised membrane potential29,84, the inactivated state has 
a longer half-life and thus the channels are more susceptible to blockade by 
LAs. Furthermore, the inhibitory effects of LAs may reduce INaP, which is 
thought to contribute to cancer cell invasiveness27. Such properties of state-
dependent blockers confer a therapeutic advantage for LAs and allow for 
discrimination between the same molecular targets under different 
conditions.  In addition to the potential benefits of local anaesthesia 
discussed earlier8-10, LAs at concentrations that are sufficient to block NaV1.5 
activity29 correspond to those given at clinical doses82, which makes them 
ideal candidates for antimetatatic drugs. 
Given the subtle differences between adult and neonatal NaV1.5 with respect 
to kinetics and voltage-dependence of gating29,30, along with the identical 
drug binding sites; it is challenging to design selective molecules for the 
neonatal splice variant. This puts a limit on the range of selectivity of 
pharmacotherapy leading researchers to explore alternative avenues. 
Antibody therapy may offer possibilities of selectivity by using antibodies 
against the neonatal splice variant. Chioni et al have developed a polyclonal 
antibody that selectively binds the neonatal splice variant, named 
NESOpAb85, which has also been shown to block neonatal NaV1.5 activity 
when applied extracellularly at concentrations of 0.05 ng/ml. Those findings 
offer promising therapeutic applications of NESOpAb for neonatal NaV1.5 
pathological expression in adult metastatic cancers.  
4.6 Clinical implications: 
 
Given the importance of VGSCs in cancer cell invasiveness, numerous in 
vitro and vivo studies have shown that inhibition of VGSC function can 
mitigate metastasis and thus such drugs can be used clinically as 
antimetastatic agents. LAs are one example, which have also been shown in 
retrospective studies to influence the outcome of surgery and reduce the 
incidence of recurrence (see introduction). To that end, LAs, such as 
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lidocaine and levobupivacaine can be re-purposed as antimetastatic drugs. 
Their use is particularly important during tumour resection where they can 
either be injected directly onto the tumour, or perfused intravenously. For the 
latter route of administration, systemic toxicity is one important consideration, 
especially cardiotoxicity as the adult NaV1.5 is functionally expressed in 
cardiomyocytes. According to this study, it can be inferred that lidocaine 
would be more suitable to be given intravenously, as it readily unbinds and 
hence would be more cardiac sparing. Whereas levobupivacaine, which is 
more potent than lidocaine, may be used for direct injection onto the tumour, 
where the microenvironment is more acidic due to inflammation. That would 
ensure that sufficient amounts are achieved locally to inhibit the VGSCs in 
the cancer cells with minimal leak to the circulation, since levobupivacaine is 
likely to be more cardiotoxic given that it fails to unbind from the channels. 
Failure of LA molecules to unbind may lead to accumulation within the 
channel. Thus, it can be inferred that irreversible blockade could potentially 
lead to toxicity, especially in cells that repetitively fire action potentials, e.g. 
cardiomyocytes. Bupivacaine, which is a racemic mixture, is reported to 
accumulate in guinea pig cardiomyocytes and thus cause cardiotoxicity86. 
Although levobupivacaine is reported to be less toxic than bupivacaine, it is 
likely to cause cardiotoxicity at physiological heart rates (60-120 beats per 
minute), where the diastolic period is not sufficient for complete recovery 
from blockade.  Lidocaine, on the other hand would be more cardiac sparing 
as it unbinds relatively quickly, and is hence safer to use intravenously either 
peri- or post-operatively in tumour resection.     
These have important implications in the clinical use of these LAs in cancer 
patients who may suffer from heart conditions, such as angina, where 
pathological changes may influence the resting membrane potential and 
hence affect the degree of inhibition and the unbinding mode of these LAs. 
Moreover, the findings from this study are also relevant for the use of 
lidocaine in neonates, since it exhibits a differential mode of unbinding and 
therefore considerations must be taken with respect to dosing regimens.  
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In addition to the use of LAs during tumour resection, they can be given as 
adjuvant drugs along with the conventional therapies for cancer for better 
management. Their clinical potential to ameliorate cancer metastasis may 
aid in turning cancer into a chronic condition. Since these drugs are already 
used clinically, there would be no issues with dosage, side effects and long-
term use. Nevertheless, new compositions of LAs and other VGSC inhibitors, 
particularly I-NaP inhibitors, e.g. ranolazine and riluzole can be modified to 
reduce their off target effects and tailor them to target VGSCs in cancer cells.  
 
5. Future work 
 
5.1Local anaesthesia in tumour resection 
LAs can either be administered directly into the tumour, or infused 
intravenously peri-, or post-operatively in an attempt to mitigate metastasis. 
Levobupivacaine coapplied with adrenaline would be suitable for the former 
method, but not the latter, for which lidocaine would be preferred due to the 
previously discussed properties of inhibition. Interestingly, the activity of the 
neonatal NaV1.5 in metastatic breast cancer cells MDA-MB-231increases 
mRNA levels and membrane expression of the channels via a PKA-mediated 
positive feedback loop58. Therefore, it is conceivable that inhibition of VGSC 
would have a dual advantage of inhibiting their activity and surface 
expression. 
Although it is established that LAs inhibit cell invasion in vitro29,41and that 
other VGSC blockers reduce metastasis in vivo61,68, it remains unclear 
whether the therapeutic benefits of LAs are directly due to inhibition of 
VGSCs. To date, LAs have not been tested on animal models of metastasis, 
of which there are few. There are no available animal models for metastatic 
colon cancer; however, the Dunning rat model for prostate cancer can be 
used as a model for metastasis87.  
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5.2The effects of lidocaine and levobupivacaine on fast and slow 
inactivation 
It is unclear from this study whether fast and slow inactivation and their 
modulation by LAs are different between the two splice variants. The steady-
state inactivation protocol used in this study examines fast inactivation. Slow 
inactivation, however, occurs in response to prolonged depolarisations. 
Therefore, to address this question the following protocol must be carried 
out. In order to examine slow inactivation a long conditioning pulse must be 
applied for 5 seconds before a hyperpolarising step to -120 mV to remove 
fast inactivation. Currents can then be elicited by a step to 0 mV to examine 
the available current in the presence and absence of LAs.  Furthermore, the 
recovery protocol used in this study examines recovery from closed-state 
inactivation at -80 mV. In order to examine recovery from fast inactivation, a 
paired pulse protocol can be used, where a conditioning pulse is applied 
initially to drive the channels into fast inactivation, after which a step to -120 
mV is applied for varying durations. A second test pulse to 0 mV can then be 
applied to measure the recovered current. The same protocol can also be 
used to examine recovery from inactivation at -90 mV, as the differential use-
dependent inhibition by lidocaine on adult and neonatal NaV1.5 may arise 
from different recovery kinetics at -90 mV.  
 
5.3Time course of recovery from local anaesthetic blockade 
Once high affinity binding of LAs to inactivated channels occurs, unbinding 
can only take place upon recovery from inactivation, which frequently occurs 
in cardiomyocytes during diastole (relaxation of heart muscles). By contrast, 
in metastatic colon cancer cells, which have a membrane potential of 
approximately -40 mV, recovery from inactivation is infrequent and a high 
proportion of the channels remain inactivated. This consequently affects the 
reversibility of lidocaine block, suggesting that the function of NaV1.5 
channels may only be reinstated upon insertion of newly translated channels 
into the membrane. This could be tested by applying lidocaine to 
HEK293cellsrecombinanatly expressing NaV1.5 channels and washing it off. 
The current density can then be measured over increasing duration of time. 
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A saturating concentration of TTX and a protein synthesis inhibitor can be 
used as positive and negative controls, respectively. These experiments 
would aid in establishing an appropriate dosing regimen.  
 
5.4The Invasion machinery of metastatic colon cancer cells 
The machinery of invasion in metastatic colon cancer cells remains elusive. 
The NaV1.5 channels are suggested to act in concert with other cellular 
components to facilitate cell invasion. To this end, the Matrigel invasion 
assay can be used to elucidate the machinery of invasion of SW620 cells as 
models of metastatic colon cancer. Extracellular acidification via the interplay 
between sodium ions and proton exchange is one proposed mechanism that 
is well established in breast cancer cells (MDA-MB-231)88. NaV1.5 and NHE1 
colocalise at focal sites of membrane remodelling in invadopodia of MDA-
MB-231 cells. Furthermore, NHE1 is allosterically regulated by NaV1.5 
activity; however, the mechanism remains unclear. The interplay between 
NaV1.5 and NHE1 leads to protonation of the extracellular environment, 
which favours the activity of cathepsins S and B, which subsequently break 
down the basement membrane. It is unclear whether this process is 
recapitulated in metastatic colon cancer cells. Another important ion 
exchange mechanism is calcium ion entry via the action of the sodium-
calcium exchanger (NCX). Transcripts of the cardiac isoform NCX1 are 
detectable in SW620 cells (unpublished data). The activity of NHE1 and 
NCX1 can be inhibited using amiloride and nickel, respectively, and their 
involvement in SW620 cell invasion can be investigated using the Matrigel 
invasion assay. In addition to ion exchange mechanismsthat require sodium 
ion influx, the expression of NaV1.5 alone may facilitate the transition to the 
metastatic phenotype through protein-protein interactions. One possible 
candidate is scotin89, which is a p53-inducable pro-apoptotic protein that is 
normally expressed in the nuclease and the endoplasmic reticulum. There is 
evidence that NaV1.5 channels physically interact with scotin (Baptista-Hon 
and Hales, unpublished data), and thus colocalise in the cell surface where 
scotin can no longer execute its pro-apoptotic function. These primary 
observations need validation and further investigation.  
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